Gsa Capital Partners LLP Avidity Biosciences, Inc. Transaction History
Gsa Capital Partners LLP
- $1.35 Billion
- Q4 2024
A detailed history of Gsa Capital Partners LLP transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 7,320 shares of RNA stock, worth $255,614. This represents 0.02% of its overall portfolio holdings.
Number of Shares
7,320Holding current value
$255,614% of portfolio
0.02%Shares
6 transactions
Others Institutions Holding RNA
# of Institutions
251Shares Held
107MCall Options Held
224KPut Options Held
161K-
Price T Rowe Associates Inc Baltimore, MD10.6MShares$371 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.23MShares$322 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$301 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.13MShares$284 Million5.95% of portfolio
-
Wellington Management Group LLP Boston, MA7.03MShares$246 Million0.06% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.82B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...